Forefront Collaborative | Updates on Alzheimer ’s Disease: Pathophysiological Perspectives, Diagnosis and Treatment Options, and Looking Ahead
Staying up to date on the latest developments in any disease state is challenging enough. But with Alzheimer’s, it can seem like the effects of the disease itself—a race against time. With that sense of urgency in mind, we collaborated with our educational partners on an interactive live activity for learners attending the 141st Annual Meeting of the American Neurological Association (ANA) in hopes of providing a robust CME experience on Alzheimer’s Disease to neurologists, primary care physicians, geriatricians, and psychiatrists who care for patients with AD. At a time and place they were likely to be. Supported by an educational grant from Lilly, our two pronged approach covered two key areas—a practical perspective on Advancements in the understanding of AD pathophysiology, and What’s Next in Diagnostic and Therapeutic Paradigms for AD? The landscape of clinical trials—important topics covering the past, the present, and what’s coming down the road for patients, caregivers, and HCPs. For those HCPs, the programs will be archived as enduring materials on the myCME educational platform.
Alzheimer's, Disease, Pathophysiological, Forefront, AD, ANA, myCME
16921
post-template-default,single,single-post,postid-16921,single-format-standard,,qode-title-hidden,qode_grid_1200,footer_responsive_adv,qode-theme-ver-9.1.2,wpb-js-composer js-comp-ver-4.11.2,vc_responsive

12 Aug Looking Ahead in Alzheimer’s Disease: Advances in Understanding of Neurobiology, Diagnostics, and Therapeutics

Alzheimer’s / Live Meeting at the 141st Annual Meeting of the American Neurological Association 

Staying up to date on the latest developments in any disease state is challenging enough. But with Alzheimer’s, it can seem like the effects of the disease itself—a race against time. With that sense of urgency in mind, we collaborated with our educational partners on an interactive live activity for learners attending the 141st Annual Meeting of the American Neurological Association (ANA) in hopes of providing a robust CME experience on Alzheimer’s Disease to neurologists, primary care physicians, geriatricians, and psychiatrists who care for patients with AD. At a time and place they were likely to be. Supported by an educational grant from Lilly, our two pronged approach covered two key areas—a practical perspective on Advancements in the understanding of AD pathophysiology, and What’s Next in Diagnostic and Therapeutic Paradigms for AD? The landscape of clinical trials—important topics covering the past, the present, and what’s coming down the road for patients, caregivers, and HCPs.

The program can be found on myCME, here.